Compare iShares Russell 2000 ETF (IWM) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs McKesson Corporation — how do they compare? iShares Russell 2000 ETF trades at $278.93 (market cap $77.70B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is the larger of the two by market cap, and McKesson Corporation pays a 0.4% dividend while iShares Russell 2000 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and McKesson Corporation for 74 Days on average.
| IWM | MCK | |
|---|---|---|
Market Cap | $77.70B | $108.46B |
Volume | 35,598,983 | 712,607 |
52-Week High | $305.06 | $995.69 |
52-Week Low | $229.13 | $725.17 |
Typical Hold Time | 83 Days | 74 Days |
Sector | — | Health |
Enterprise Value | — | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM trades at $278.93, up 0.44% with a bearish technical signal from moving averages. The ETF faces headwinds as small-caps underperform the broader market, with recent news highlighting decade-long trailing of the S&P 500. Technical indicators show mixed signals with RSI neutral but ADX signaling strong bearish momentum. Support levels cluster around $272-$276 while resistance sits at $279-$282.
The outlook remains cautious given small-cap sensitivity to interest rates and economic conditions. Recent Fed rate hikes pressure the sector, though some rotation potential exists if market breadth improves. Key risks include continued underperformance versus large-caps and sensitivity to tightening financial conditions.
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
